Clinical and immunologic effects of T-activin therapy in early stage melanoma patients.
Comparison in people · 1996
- What was studied
- 17 melanoma patients: 8 surgery plus T-activin; 9 surgery-only controls
- Main finding
- In a 17-person melanoma comparison, the survival difference with T-activin added to surgery was not statistically significant; immune-cell changes did not track clinical benefit.
Reported survival time · 40 versus 24 months · T-activin + surgery versus surgery alone · Reported follow-up · Not statistically significant
Reported findings and study design
In a 17-person melanoma comparison, the survival difference with T-activin added to surgery was not statistically significant; immune-cell changes did not track clinical benefit.
T-activin + surgery 8; surgery alone 9; early-stage melanoma; follow-up February 1991–August 1995.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported survival time | 40 versus 24 months | T-activin + surgery versus surgery alone · Reported follow-up · Not statistically significant |
| Disease-free interval | 17.5 versus 13 months | Same comparison; described as similar |
| Lymphoproliferative response | Increase in 4 of 5 treated patients with progression | Biological response did not correspond to clinical benefit |
| Participants | 8 treated; 9 controls |
The survival-time summary is not labeled as a median in the abstract. The small, non-randomized study does not establish a cancer-survival benefit.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- Very small adjunctive comparison; random allocation and blinding are not established by the abstract.
- Immune-marker changes did not correlate with clinical course and should not be presented as proven cancer benefit.
Source details
Journal article
Original publication metadata and indexed abstract checked; full methods and tables not appraised.
Indexed abstract reviewed
Sources checked
Citation
N. Stanojević-Bakić, D. Milosević, L. Vucković-Dekić, M. Sasić, L. Marković. Clinical and immunologic effects of T-activin therapy in early stage melanoma patients. Neoplasma. 43(4):245–252